search
Englishexpand_more
Deutsch
Français
Contact us
search
ENG
Deutsch
Français
Contact us
  • There are no suggestions because the search field is empty.
Blog Hero
Blog

Why You Should Start Collecting Clinical Data Early Under EU MDR

Clinical data is the backbone of Medical Device compliance under the EU MDR. Discover the benefits of starting data collection early, and the risks of delaying.

Manufacturers should start collecting clinical data during product development, not when the submission is due. Under EU MDR Article 61 and Annex XIV, clinical evaluation is a continuous process, and Notified Bodies expect sufficient clinical evidence to support conformity with the General Safety and Performance Requirements (GSPRs). Early planning is the most practical way to avoid non-conformities and delays.

Clinical data is the backbone of medical device compliance under EU MDR, yet it is still one of the most neglected parts of development. Teams put their energy into engineering milestones, technical testing, and the submission itself, then discover late that the clinical evidence strategy has gaps. Under EU MDR that discovery is expensive: delayed certification, claims that have to be removed, and remediation that could have been planned months earlier.

When should manufacturers start collecting clinical data under EU MDR?

Manufacturers should plan clinical data collection during product development, well before the regulatory submission. EU MDR treats clinical evaluation as a continuous process across the device lifecycle (Article 61 and Annex XIV), so evidence gathered early feeds the design, the risk management file, and the Clinical Evaluation Report (CER), and later supports post-market activities.

The primary goal of clinical evaluation under MDR is to show sufficient evidence of conformity with the GSPRs: that the device delivers safety, performance, and an acceptable benefit-risk ratio under normal conditions of use. Our guide on how to write a clinical evaluation under EU MDR covers the writing side. Notified Bodies frequently flag insufficient clinical data as a major non-conformity, and planning early reduces the risk of findings that delay CE marking.

What counts as clinical data under EU MDR?

Under EU MDR Article 2(48), clinical data is information on the safety or performance of a device that is generated from its use. It does not come from clinical studies alone. The main sources are clinical investigations of the device, published literature on the device or an equivalent device, and post-market surveillance data, particularly post-market clinical follow-up (PMCF).

Source of clinical data

What it gives you

Related Qserve service

Clinical investigations of the device concerned

New data generated specifically on your device

Clinical trials

Published scientific literature on the device or an equivalent device

Existing peer-reviewed data on your device or one shown to be equivalent

Clinical evaluation

Post-market surveillance, particularly PMCF

Real-world data collected after the device is on the market

PMCF surveys and studies

 

Knowing which of these sources you can realistically rely on is what shapes the rest of the strategy.

Which questions should you answer before planning clinical data collection?

Three questions shape an early clinical evidence strategy: what evidence already exists, whether it is sufficient for the intended purpose and claims, and where the gaps are. Answering them during development shows whether existing data can carry the clinical evaluation or whether a clinical investigation or PMCF activity needs to be planned.

  1. What evidence is already available? Are there existing clinical studies, published literature, registry data, or data from equivalent devices?
  2. Is the evidence sufficient? Does it support the intended purpose, indications, clinical benefits, and all device claims? Is the data high quality and representative of the target population?
  3. Are there gaps? What data is missing, and how can it be addressed? Is a new clinical investigation required, or would a robust PMCF survey be sufficient?

To test where you stand, our free Clinical Evaluation Readiness check is a quick way to start.

What are the benefits of collecting clinical data early under EU MDR?

Collecting clinical data early lets manufacturers close evidence gaps before the Notified Body reviews the clinical evaluation. Well-documented data tied to the intended purpose and claims reduces the risk of major non-conformities under Article 61 and Annex XIV, informs design and risk management before design freeze, and avoids last-minute studies that delay CE marking.

  • Supports Article 61 and Annex XIV requirements. Early data gives you sufficient clinical evidence to demonstrate conformity with the GSPRs.
  • Makes Notified Body review more straightforward. Robust, well-documented data reduces the risk of major non-conformities and delays during conformity assessment.
  • Speeds up Clinical Evaluation Report (CER) writing. Early evidence is a core input for the CER, which must be kept up to date as a living document throughout the device lifecycle.
  • Feeds design and risk management. Data collected during development can surface safety or performance issues early enough for corrective action before design freeze.
  • Lays the foundation for PMCF. Early data collection makes post-market clinical follow-up plans more meaningful and keeps ongoing compliance on track.
  • Reduces time-to-market risk. You avoid last-minute evidence gaps that could hold up CE marking.
  • Improves cost efficiency. Finding gaps early prevents expensive redesigns and additional studies later.

What are the risks of delaying clinical data collection?

Delaying clinical data collection exposes manufacturers to four main risks: Notified Body non-conformities that hold up CE marking, long timelines if a new clinical investigation turns out to be necessary, postponed revenue, and claims or indications that must be removed because the evidence cannot support them.

  • Regulatory setbacks. Insufficient clinical evidence often leads to major non-conformities, which delay CE marking or trigger costly remediation.
  • Longer clinical study timelines. If a new investigation is required, planning and execution can take months or years, pushing back market entry.
  • Economic losses. A delayed CE mark postpones commercialization and the revenue that comes with it.
  • Dropped claims or indications. If the data cannot support a specific claim, it has to be removed, which reduces the device’s market potential and competitiveness.

Takeaway

Early clinical data collection under EU MDR is more than a regulatory obligation. Manufacturers that build clinical evidence planning into development protect both the CE marking timeline and the claims their commercial case depends on. The practical starting point is the three questions above: what you have, whether it is enough, and what is missing.

How can Qserve help you plan clinical evidence early?

Qserve’s clinical teams help manufacturers run an early clinical gap analysis, define a clinical strategy, write the Clinical Evaluation Plan (CEP), and set up PMCF activities or clinical investigations. As a medical device CRO with clinical evaluation expertise, Qserve supports manufacturers still in development as well as those further along the device lifecycle.

Whether you are still in the product development stage or already navigating later phases of the device lifecycle, our experts can help you design a proactive, compliant, and cost-effective approach to clinical evidence under EU MDR. The aim is fewer surprises at Notified Body review and a clearer path to CE marking. Read more about our clinical strategy support or contact our clinical team to discuss your evidence gaps.